Top Markets
Coin of the day
Oragenics, Inc. Oragenics, Inc.

Oragenics, Inc.

OGEN
Rang in aandelen #36713
Oragenics, Inc. (OGEN) is a U.S.-based biotechnology firm primarily focused on... Oragenics, Inc. (OGEN) is a U.S.-based biotechnology firm primarily focused on creating treatments for infectious diseases. Among its pipeline assets are two vaccine candidates designed to combat the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2): NT-CoV2-1, an intranasal formulation, and Terra CoV-2, an intramuscular option. Beyond its infectious disease focus, Oragenics also has other experimental treatments under development, including LPT3-04, targeting weight loss, and SMaRT Replacement Therapy, a topical solution aimed at preventing dental cavities. Strategic alliances are also a part of its operations. This includes a licensing deal with Noachis Terra Inc. for patents and biological resources related to pre-fusion coronavirus spike proteins. Additionally, Oragenics is collaborating with Precigen, Inc. and ILH Holdings, Inc. on the advancement and market introduction of MU1140 and its associated compounds. Established in 1996, the company, formerly known as Oragen, Inc., maintains its headquarters in Tampa, Florida.
Aandeelprijs
$0.5301
Laatst gesynchroniseerd: 2026-08-14
Marktkapitalisatie
$2.39M
Verandering (1 dag)
0.00%
Verandering (1 jaar)
-53.90%
Land
US
Handel Oragenics, Inc. (OGEN)

Categorie

EPS voor Oragenics, Inc. (OGEN)
EPS per 2026 TTM: 0
Volgens de laatste financiële rapporten en de aandelenkoers van Oragenics, Inc. is de huidige EPS van het bedrijf (TTM) 0. Eind 2026 had het bedrijf een EPS van 0, gelijk aan de EPS van 2026 die 0 bedroeg.
EPS-geschiedenis van Oragenics, Inc. van 2026 tot 2026
EPS aan het einde van elk jaar
Jaar EPS Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
EPS van vergelijkbare bedrijven of concurrenten